Examine the level of chimerism required to maintain both graft survival as well as hematologic normalcy using a regimen containing pentostatin, cyclophosphamide, alemtuzumab, and low total body irradiation.

162

All

4 Years to 80 Years (Child, Adult, Older Adult)

NCT02105766

14007714-H-0077

December 21, 2013

August 31, 2021

August 31, 2021

April 7, 2014

February 5, 2019

National Institutes of Health Clinical Center, 9000 Rockville PikeBethesda, Maryland, United States

treatment success at one year, defined as full donor type hemoglobin on hemoglobin electrophoresis for patients with SCD and transfusion-independence for patients with thalassemia and DBA.

The level of chimerism required to maintain both graft survival as well as hematologic normalcy. The chimeric status of patients will be measured on days, +30, +60 and +100 by microsatellite analysis of the peripheral blood. More frequent monito...

The chimeric status of patients will be measured on days, +30, +60 and +100 by microsatellite analysis of the peripheral blood. More frequent monitoring may be required.

(and 6 more...)

150

All

2 Years to 65 Years (Child, Adult, Older Adult)

NCT00061568

03017003-H-0170

July 16, 2004

January 31, 2020

January 31, 2020

May 29, 2003

March 5, 2019

National Institutes of Health Clinical Center, 9000 Rockville PikeBethesda, Maryland, United States